Agomab Announces Closing of Initial Public Offering

Rhea-AI Summary

Agomab (Nasdaq: AGMB) closed its initial public offering of 12,500,000 ADSs at $16.00 per ADS, generating approximately $200.0 million in gross proceeds before underwriting discounts, commissions and offering expenses. The ADSs began trading on the Nasdaq Global Select Market on February 6, 2026.

Joint book-running managers included J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen; the registration statement was declared effective January 30, 2026.

Positive

• Gross proceeds of approximately $200.0 million
• Issued 12,500,000 ADSs at $16.00 per ADS
• Nasdaq Global Select listing (AGMB) effective February 6, 2026

Negative

• Net proceeds reduced by underwriting discounts, commissions and offering expenses
• Offering limited outside the United States and subject to jurisdictional restrictions

Market Reaction

+4.62% $16.12

15m delay 31 alerts

+4.62% Since News

+152.0% Peak in 3 min

$16.12 Last Price

$14.51 $51.50 Day Range

+$34M Valuation Impact

$761M Market Cap

0.3x Rel. Volume

Following this news, AGMB has gained 4.62%, reflecting a moderate positive market reaction. Argus tracked a peak move of +152.0% during the session. Our momentum scanner has triggered 31 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $16.12. This price movement has added approximately $34M to the company's valuation.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

ADSs Offered: 12,500,000 ADSs Common Shares Represented: 12,500,000 shares IPO Price: $16.00 per ADS +3 more

6 metrics

ADSs Offered 12,500,000 ADSs Initial public offering size

Common Shares Represented 12,500,000 shares Common shares represented by ADSs in IPO

IPO Price $16.00 per ADS Public offering price for IPO

Gross Proceeds $200.0 million Aggregate gross proceeds before fees

SEC Effectiveness Date January 30, 2026 Registration statement declared effective

Nasdaq Listing Date February 6, 2026 ADSs began trading on Nasdaq Global Select Market

Market Reality Check

Price: $15.61 Vol: Volume 2,321,180 is at 0....

normal vol

$15.61 Last Close

Volume Volume 2,321,180 is at 0.98x the 20-day average of 2,361,844, suggesting typical trading activity around the IPO news. normal

Technical Shares trade below the 200-day MA of 14.65, indicating limited technical momentum prior to this IPO closing announcement.

Market Pulse Summary

This announcement confirms the closing of Agomab’s IPO of 12,500,000 ADSs at $16.00 per ADS, raising...

Analysis

This announcement confirms the closing of Agomab’s IPO of 12,500,000 ADSs at $16.00 per ADS, raising gross proceeds of $200.0 million. The ADSs began trading on Nasdaq on February 6, 2026 under ticker AGMB, following SEC effectiveness on January 30, 2026. Investors may track how the new capital supports Agomab’s clinical programs and how trading develops relative to the IPO price and deal size.

Key Terms

american depositary shares, initial public offering, nasdaq global select market, registration statement, +1 more

5 terms

american depositary shares financial

"initial public offering of 12,500,000 American Depositary Shares (“ADSs”)"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

initial public offering financial

"announced the closing of its previously announced initial public offering of 12,500,000"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

nasdaq global select market financial

"The ADSs began trading on the Nasdaq Global Select Market on February 6, 2026"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

registration statement regulatory

"A registration statement relating to this offering has been filed with the Securities"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

prospectus regulatory

"The offering was made only by means of a prospectus. Copies of the final prospectus may"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. Not financial advice.

ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the closing of its previously announced initial public offering of 12,500,000 American Depositary Shares (“ADSs”) representing 12,500,000 of its common shares, at a public offering price of $16.00 per ADS. The aggregate gross proceeds to Agomab from the offering were approximately $200.0 million, before deducting underwriting discounts and commissions and offering expenses.

The ADSs began trading on the Nasdaq Global Select Market on February 6, 2026 under the ticker symbol “AGMB”.

J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen acted as joint book-running managers for the offering.

A registration statement relating to this offering has been filed with the Securities and Exchange Commission and was declared effective on January 30, 2026. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; and Van Lanschot Kempen (USA) Inc., 880 Third Avenue, 17th floor, New York, New York 10022, or by email at usa@vanlanschotkempen.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium. The transaction to which this press release relates was available only to, and was engaged in only with, in member states of the European Economic Area (including Belgium), persons falling within the meaning of Article 2(e) of Regulation (EU) 2017/1129 on the prospectus published when securities were offered to the public or admitted to trading on a regulated market, and in the United Kingdom, investment professionals falling within article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), persons falling within article 49 (2), (a) to (d) of the Order and other persons to whom it may lawfully be communicated.

About Agomab

Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Agomab’s product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches. Agomab’s mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding Agomab’s focus on the discovery and development of its pipeline of novel product candidates for chronic fibrotic disorders. Forward-looking statements are based on Agomab’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the risks inherent in biopharmaceutical product development. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” section of the registration statement filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Agomab undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information on this page as current or accurate after its publication date.

Contacts

Investors
Sofie Van Gijsel
VP of Investor Relations
E-Mail: sofie.vangijsel@agomab.com
Phone: +1 781 296 1143

Media
Eva Mulder
Trophic Communications
E-Mail: agomab@trophic.eu
Phone: +31 6 52 33 15 79

FAQ

How many shares did Agomab (AGMB) sell in the February 2026 IPO?

Agomab sold 12,500,000 ADSs in the initial public offering. According to the company, each ADS represents one common share and the offering priced at $16.00 per ADS, on February 6, 2026.

What were the gross proceeds for Agomab (AGMB) from the IPO?

The IPO generated approximately $200.0 million in gross proceeds before fees. According to the company, this amount is prior to underwriting discounts, commissions and offering expenses.

When did Agomab (AGMB) begin trading on Nasdaq and under what ticker?

Agomab began trading on the Nasdaq Global Select Market on February 6, 2026 under the ticker AGMB. According to the company, the listing follows a registration statement declared effective January 30, 2026.

Who were the joint book‑running managers for Agomab's (AGMB) IPO?

The IPO's joint book‑running managers were J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen. According to the company, these firms led the syndicate for the offering.

Will Agomab's (AGMB) IPO proceeds be net of fees and expenses?

The reported $200.0 million is gross proceeds and does not reflect fees or expenses. According to the company, underwriting discounts, commissions and offering expenses will reduce the net proceeds available to Agomab.